Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

Latest from Mays Cancer Center at UT Health San Antonio

Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

July 25, 2022

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer

May 09, 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 06, 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.